The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABA B Receptors with Arbaclofen
Open accessAbstract
Pharmacological activation of the GABA B receptor with arbaclofen in a mouse model of fragile X syndrome corrects neuronal defects associated with the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activation of the GABA B receptor by arbaclofen decreased mRNA translation in the cortex of fragile X mice and corrected the increased spine density 78 .”
From Progress toward treatments for synaptic defects in autism (2013) · cites this paper as [78]
In the citing paper
“Administration of GABAB agonists, such as baclofen or arbaclofen, corrects exacerbated protein synthesis and multiple phenotypes in Fmr1-KO mice37–39.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [37]
In the citing paper
“treatment with mGluR antagonists (mavoglurant) and GABAB agonists (arbaclofen), as well as gene reinstatement in Fmr1-KO mice starting in young adult or adult mice, can fully correct most behavioural, physiological, biochemical and neuroanatomical alterations30,32,37.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [37]
In the citing paper
“No human data are available for SCA1 in the absence of a drug suitable for clinical trials30,32,37.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [37]
In the citing paper
“For many subtypes of ASD, there is a GABAB deficit and arbaclofen has rescued the behavioral deficits including social deficits in the mouse models of idiopathic ASD [127], deletion of 16p11.2 [128], and FXS [129].”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malenka, R. C., & Bear, M. F. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.012 · Cited by 3,968
Self-citationVerkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Self-citationFMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072
Kaech, S., & Banker, G. A. (2006) · Nature Protocols · doi:10.1038/nprot.2006.356 · Cited by 1,766
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Self-citationAltered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Self-citationMorphometric study of human cerebral cortex development
Huttenlocher, P. R. (1990) · Neuropsychologia · doi:10.1016/0028-3932(90)90031-i · Cited by 1,239
Culturing hippocampal neurons.
Tanaka, H. (2002) · Folia Pharmacologica Japonica · doi:10.1254/fpj.119.163 · Cited by 1,141
Kanai, Y., Dohmae, N., & Hirokawa, N. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.022 · Cited by 1,109
Fmr1 knockout mice: A model to study fragile X mental retardation
THEDUTCHBELGIANFRAGILEXCONSOR (1994) · Cell · doi:10.1016/0092-8674(94)90569-x · Cited by 1,108
Cited by
Sorted by citations
Items 201–248 of 248
GABA-independent activation of GABAB receptor by mechanical forces
Huo, Y., Zhou, Y., Li, L., Yang, F., Meng, J., He, F., Zhang, F., Song, M., Shen, C., Liu, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64811-2 · Cited by 3
Stanfield, A. C., & McKechanie, A. G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2510408 · Cited by 3
Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome
Scharf, S. H., Gasparini, F., Spooren, W. P. J. M., & Lindemann, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00018-4 · Cited by 3
Hoffmann, A., & Berry‐Kravis, E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800109-7.00020-0 · Cited by 3
From bedside to bench and back: Translating ASD models
Drozd, H. P., Karathanasis, S. F., Molosh, A. I., Lukkes, J. L., Clapp, D. W., & Shekhar, A. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.10.003 · Cited by 3
How copy number variations shape brain developmental disorders: Unraveling the synaptic puzzle
Wang, T., TRABZONLU, K., Jones, E. F., & Syed, Y. A. (2025) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.70009 · Cited by 2
Wilson, M. A., Sumera, A., Berk, E., & Booker, S. A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1640921 · Cited by 2
A human electrophysiological signature of Fragile X pathophysiology is shared in V1 of Fmr1-/y mice
Kornfeld-Sylla, S. S., Gelegen, Ç., Norris, J. E., Chaloner, F. A., Lee, M., Khela, M., Heinrich, M. J., Finnie, P. S. B., Ethridge, L. E., Erickson, C. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69243-0 · Cited by 3
Self-citationSynaptic protein mutations in autism
Sauer, A. K., Walsh, J. A., Curran, D., Zohourian, N., Stanton, J. E., Zabetakis, I., Brown, J. A. L., & Grabrucker, A. M. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107365 · Cited by 4
Reflections on Clinical Trials in Fragile X Syndrome
Jønch, A. E., & Jacquemont, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00020-2 · Cited by 2
Medication Management of Fragile X Syndrome
Erickson, C. A., Wink, L. K., Schaefer, T. L., & Shaffer, R. C. (2013) · Springer eBooks · doi:10.1007/978-1-4614-4788-7_188 · Cited by 2
Chloride imbalance in Fragile X syndrome
Miles, K. D., & Doll, C. A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1008393 · Cited by 1
Fang, M., Deibler, S. K., Krishnamurthy, P. M., Wang, F., Rodríguez, P. M., Banday, S., Virbasius, C.-M. A., Sena‐Esteves, M., Watts, J. K., & Green, M. R. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1348478 · Cited by 1
Vlachou, S. (2024) · The Receptors · doi:10.1007/978-3-031-67148-7_10 · Cited by 1
Hu, Y., Wu, Y., Wei, M., Ma, J., Lin, J., Chen, G., Li, Q., Zhang, J., Wang, R., Zhu, Y., et al. (2026) · Science Advances · doi:10.1126/sciadv.aea3775 · Cited by 1
A microglial basis for fragile X syndrome via impairment of FMRP-regulated lysosomal function
Li, H., Choi, J. J.-Y., Huang, E. J., & Xu, B. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03927-3 · Cited by 1
The Evolving Role and Nature of Gene Mutations in the Neuropathology of Autism Spectrum Disorders
Tchaconas, A. (2022) · Columbia Undergraduate Science Journal · doi:10.52214/cusj.v7i.6368 · Cited by 1
Phase II and III drugs for the treatment of fragile X syndrome
Politte, L. C., & McDougle, C. J. (2012) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2013.750240 · Cited by 1
Targeting the GABAB Receptor in Fragile X Syndrome and Autism Spectrum Disorders
Healy, A. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-46044-4_13 · Cited by 1
Self-citationTranslation in fragile X: no home runs in the first at-bat
Veenstra-VanderWeele, J. M. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9204-y · Cited by 1
Kamm, C. (2013) · Clinical Investigation · doi:10.4155/cli.13.45
Childhood Disorders of the Synapse: Challenges and Opportunities
HUGHES, V. A., Sheng, M., & Zoghbi, H. Y. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004356
Fragile X Syndrome: Steps towards Therapy
Pop, A. (2013) · RePub (Erasmus University Rotterdam)
Trialing targeted therapies for autism
Murphy, D., & Ecker, C. (2012) · Nature Medicine · doi:10.1038/nm.3027
What Mechanisms Induce Methylation of FMR1 Gene Full Mutation? A Still Unanswered Question
Tabolacci, E., & Neri, G. (2016) · Epigenetics and human health · doi:10.1007/978-3-319-27186-6_8
A-to-I RNA Editing in Autism Spectrum Disorder
Eran, A., Kohane, I. S., & Kunkel, L. M. (2014) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814602167_0010
Rendall, A. R. (2017) · OpenCommons at University of Connecticut (University of Connecticut)
Novel Approaches for Treating Pediatric Psychiatric Disorders
Prasad, S., & Cook, E. H. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0067
Altered visual evoked potentials associated with verbal and nonverbal skills in Fragile X syndromePreprint
Saoud, E., Fitzgerald, J., Hartney, M., & Wilkinson, C. L. (2022) · medRxiv · doi:10.1101/2022.07.10.22277277
Sleep problems in old age: metabotropic glutamate receptor to the rescue
Inami, S., Afonso, D. J. S., & Koh, K. (2023) · SLEEP · doi:10.1093/sleep/zsad044
Trials of arbaclofen for autism yield mixed results
Guglielmi, G. (2023) · The Transmitter · doi:10.53053/yuen1688
Excitation-inhibition imbalance in Neurexin-1α mutant mice is rescued by administering arbaclofenPreprint
Østergaard, F. G., & Kas, M. J. (2025) · Research Square · doi:10.21203/rs.3.rs-7426046/v1
Heinrich, M. J., & Bear, M. F. (2025) · Journal of Neurophysiology · doi:10.1152/jn.00241.2025
Self-citationUtami, K. H., Yusof, N. A. B. M., Kwa, J. E., Peteri, U.-K., Castrén, M. L., & Pouladi, M. A. (2020) · Figshare · doi:10.6084/m9.figshare.12381263
Jonak, C. R., Pedapati, E. V., Schmitt, L. M., Assad, S. A., Sandhu, M. S., DeStefano, L. A., Ethridge, L. E., Razak, K. A., Sweeney, J. A., Binder, D. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21220105
Wilkinson, C. L., & Nelson, C. A. (2021) · Figshare · doi:10.6084/m9.figshare.14121553
Jonak, C. R., Pedapati, E. V., Schmitt, L. M., Assad, S. A., Sandhu, M. S., DeStefano, L. A., Ethridge, L. E., Razak, K. A., Sweeney, J. A., Binder, D. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21220108
Studying Neuronal Connectivity in the Mouse Brain in Normal Condition and Fragile X Syndrome
Haberl, M. G. (2014) · theses.fr (ABES) · doi:10.70675/cbb47168z82fbz41a1z9174zd9e36b2b5a6d
Varela, A. S. (2017) · theses.fr (ABES) · doi:10.70675/44bdf5f9z1cdfz45e9za0cbz0b197ad4ed9d
Pathophysiological consequences of a Fragile X missense mutation
Garcia, M. P. (2020) · theses.fr (ABES) · doi:10.70675/b8e86263z5926z4a83zbaf6z0f61bf2d15f9
Etude de la contribution de l'hormone adipocytaire leptine dans la pathogenèse du syndrome de Rett
Belaïdouni, Y. (2022) · theses.fr (ABES) · doi:10.70675/f69d2875zfa9fz4465z917eza8e7b93935c6
BKCa channels as therapeutic targets in neurodevelopmental disorders : focus on acoustic dysfunction
Ferraguto, C. (2024) · theses.fr (ABES) · doi:10.70675/38217611z1b01z43f4zb4b0z72d28aca79c3
Pathophysiology of the FMRP-R138Q Fragile X Syndrome missense mutation in mice
Chato-Astrain, I. (2025) · theses.fr (ABES) · doi:10.70675/ce8d1ccfz4554z4c55z8782z624e392f72a1
Varman, D. R., Martínez‐Torres, A., Gutiérrez-Alvarado, M. E., Arellano, R. O., & Reyes‐Haro, D. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6030046
Xu, D., Zhang, B., Jiang, P., Zhu, P., Mi, D., Huang, W., Ba, R., & Zhao, C. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-026-01727-x
Metadata
- Authors
- Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., Brynczka, C., Rush, R., Thomas, A., Paylor, R., Warren, S. T., Vanderklish, P. W., Kind, P. C., Carpenter, R. L., Bear, M. F., & Healy, A. M.
- Affiliations
- Seaside Therapeutics (United States) (US)
- University of Edinburgh (GB)
- Emory University (US)
- Baylor College of Medicine (US)
- Scripps Research Institute (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Healy, Aileen M.
- Venue
- Science Translational Medicine
- Published
- 2012-09-19
- Volume
- 4
- Issue
- 152
- Pages
- 152ra128-152ra128
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC8826584
- OpenAlex
- W2096270532
- Cited by
- 249
- References
- 102
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 9 · 2023: 8 · 2022: 20 · 2021: 21 · 2020: 10 · 2019: 20 · 2018: 8 · 2017: 32 · 2016: 14 · 2015: 25 · 2014: 24 · 2013: 31 · 2012: 11
- FWCI
- 17.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 24064, HD020521, R01HD020521, P30HD024064, R37HD020521)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Keywords
- fragile X syndrome, GABAB receptors, baclofen, Fmr1 knockout mice, FMRP, synaptic protein synthesis, dendritic spine morphology, AMPA receptor internalization, mRNA translation, synaptic dysfunction, intellectual disability, autism spectrum disorder, hippocampus
- MeSH terms
- Animals, Baclofen, Behavior, Animal, Disease Models, Animal, Fragile X Syndrome, Hippocampus, Male, Phenotype, Polyribosomes, Seizures, Synapses, Protein Biosynthesis, Receptors, GABA-B, Receptors, AMPA, Mice, Knockout, Protein Transport, Dendritic Spines, Mice, Fragile X Messenger Ribonucleoprotein 1, GABA-B Receptor Agonists, Drinking Water
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
